Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Medical Journal ; (24): 1907-1909, 2009.
Artigo em Inglês | WPRIM | ID: wpr-240773

RESUMO

<p><b>BACKGROUND</b>Bacterial infection can pose a substantial diagnostic dilemma. (99m)Tc-labeled ciprofloxacin (CPF) was developed as a biologically active radiopharmaceutical to diagnose infection. In the present research, we studied the biodistribution and imaging properties of infection tracer (99m)Tc-CPF in a mouse model of infection.</p><p><b>METHODS</b>CPF was labeled with (99m)Tc and the radiochemical purity and labeling rate were measured. A mouse model of infection was established. We then determined the biodistribution of (99m)Tc-CPF and conducted the whole body scintigraphy of the animal model.</p><p><b>RESULTS</b>(99m)Tc-Ciprotech was stable for at least 6 hours at room temperature. The labeling rate of CPF by (99m)Tc was over 90%. Clearance of radioactivity mainly occurred in the liver and kidney, and the clearance from blood was rapid. Both biodistribution and imaging results showed higher uptake of (99m)Tc-CPF at sites of infection. The infectious tissue/normal tissue ratio peak was 4.30 at 4 hours after injection.</p><p><b>CONCLUSIONS</b>(99m)Tc-CPF is a sensitive radiopharmaceutical for scintigraphy of infectious lesions and it is easy to prepare.</p>


Assuntos
Animais , Camundongos , Anti-Infecciosos , Química , Farmacocinética , Infecções Bacterianas , Diagnóstico , Ciprofloxacina , Química , Farmacocinética , Modelos Animais de Doenças , Marcação por Isótopo , Métodos , Camundongos Endogâmicos BALB C , Compostos de Organotecnécio , Química , Distribuição Tecidual
2.
Chinese Journal of Oncology ; (12): 180-182, 2005.
Artigo em Chinês | WPRIM | ID: wpr-331196

RESUMO

<p><b>OBJECTIVE</b>To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis.</p><p><b>METHODS</b>Forty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C).</p><p><b>RESULTS</b>The overall pain relief rate was 73.3%, 80.0%, 100.0% in groups A, B and C. The response rate of bone metastasis was 40.0%, 33.3%, 66.7% in groups A, B and C respectively. The therapeutic effect of group C was better than those of groups A and B (P < 0.05), without any significance in the difference (P > 0.05).</p><p><b>CONCLUSION</b>The therapeutic effect of (188)Re-HEDP combined with pamidronate for breast cancer with bone metastasis is remarkable in bone pain relief and bone metastasis control, which is better than either (188)Re-HEDP or pamidronate alone.</p>


Assuntos
Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Antineoplásicos , Usos Terapêuticos , Neoplasias Ósseas , Terapêutica , Neoplasias da Mama , Tratamento Farmacológico , Patologia , Radioterapia , Antígeno Carcinoembrionário , Sangue , Terapia Combinada , Difosfonatos , Usos Terapêuticos , Ácido Etidrônico , Usos Terapêuticos , Seguimentos , Compostos Organometálicos , Usos Terapêuticos , Dor , Manejo da Dor , Radioisótopos , Usos Terapêuticos , Rênio , Usos Terapêuticos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA